← Back to patent-cliff list
Cilostazol/Borneol
Tier C — Watch / tradeCilostazol/Borneol
-
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：PDE3
Indications (approved)：穿支动脉梗死, Cerebral infarction, Stroke, Ischaemic stroke, Arterial occlusive disease, 脑小血管疾病
Regional status
US
-
EU
-
China
Phase III
2025-07-15
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Cilostazol/Borneol?
Approved indications include: 穿支动脉梗死, Cerebral infarction, Stroke, Ischaemic stroke, Arterial occlusive disease, 脑小血管疾病.
When does the Cilostazol/Borneol patent expire?
No public expiry year is available for Cilostazol/Borneol yet; this page updates once verified.
How do I get a quote for Cilostazol/Borneol intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-30